In China, primary liver cancer mostly develops from viral hepatitis, and its incidence and mortality rate are now statistically ranked third. Early detection and treatment have been extensively reported in the literature, and their 5-year survival rates have been significantly improved, both in terms of prolonging patients’ lives, improving the quality of survival, and reducing their costs. How to monitor these patients is currently based on the annual Asia-Pacific Liver Conference and the annual European Liver Conference guidelines AFP is not in the recommended screening, while abdominal B-mode ultrasonography has a high sensitivity, specificity, positive predictive value and negative predictive value, so ultrasound is a good surveillance approach. The vast majority of experts in Europe and the United States recommend monitoring every 6 months. Patients with cirrhosis who are found to have nodules on screening need only imaging without histology to diagnose hepatocellular carcinoma. Imaging methods include CT MRI, enhanced ultrasound, etc. The accuracy of the diagnosis depends on the size of the nodule. Nodules larger than 2 cm in diameter require only one imaging method to confirm the diagnosis. In contrast, for nodules 5-20 mm, it is possible that 2/3 of nodules are missed even when combining both methods. In these patients where imaging is difficult to confirm the diagnosis, liver histology aspiration or close ultrasound testing is required. There are also some serologic tests available, but they are mostly limited to hospital use. There is therefore an ongoing need to develop more advanced serum markers to extend liver cancer screening, currently limited to hospitals, to the community.